MedTrace Logo

PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer

NCT02994888 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2016-12-19

No results posted yet for this study

Summary

PROSPECT-C is a phase II study investigating the molecular markers of response or resistance to anti-epidermal growth factor receptor (EGFR) antibodies.

Conditions

Interventions

DRUG

Cetuximab

All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression

Sponsors & Collaborators

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United Kingdom

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02994888 on ClinicalTrials.gov